Evotec subsidiary moves JST-018 orthopoxvirus antibodies into Phase 1
First-in-human Phase 1 study has started for investigational orthopoxvirus antibodies developed under the U.S. Department of War Accelerated Antibodies Program, supporting biodefense countermeasures.
S. Department of War Accelerated Antibodies Program. The program is intended to support countermeasures against orthopoxviruses, a high-priority biological threat family that includes the viruses responsible for smallpox. POD® Redmond facility.
The company said the effort is designed to show a scalable model for development and continuous manufacturing for biodefense preparedness.